Organization (Other)
pharmaand GmbH
ClinicalTrials.gov lists pharmaand GmbH as lead sponsor of 22 trials. It has 57 active development programs and 15 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers pharmaand GmbH: 22 lead-sponsored trials and 1 legal-entity registration.
Disease areas (28)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Ovarian Neoplasms | 9 |
| Fallopian Tube Neoplasms | 8 |
| Carcinoma, Ovarian Epithelial | 5 |
| Recurrence | 4 |
| Breast Neoplasms | 2 |
Showing 5 of 28 disease areas.
Trials by start year as sponsor or collaborator (10)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2021 | 1 |
| 2020 | 1 |
| 2019 | 5 |
| 2018 | 4 |
| 2017 | 3 |
| 2016 | 3 |
| 2014 | 2 |
| 2013 | 1 |
| 2011 | 1 |
| 2010 | 1 |
Recruitment duration, a model prediction: none of the 22 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (57)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| RUCAPARIB | Ovarian Neoplasms | Phase 3 | 8 |
| RUCAPARIB | Fallopian Tube Neoplasms | Phase 3 | 7 |
| RUCAPARIB | Carcinoma, Ovarian Epithelial | Phase 3 | 4 |
| NIVOLUMAB | Ovarian Neoplasms | Phase 3 | 2 |
| NIVOLUMAB | Fallopian Tube Neoplasms | Phase 3 | 2 |
Showing 5 of 57 active programs.
Approved assets (15)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| RUCAPARIB | 17 |
| NIVOLUMAB | 2 |
| Sacituzumab Govitecan | 1 |
| Caffeine | 1 |
| Rucaparib Camsylate | 1 |
Showing 5 of 15 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 65% hit target (n=17) | 47% on time (n=17) |
Journals published in (18)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The Lancet. Oncology | 5 |
| British journal of cancer | 2 |
| Cancer chemotherapy and pharmacology | 2 |
| Gynecologic oncology | 2 |
| International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | 2 |
Showing 5 of 18 journals.
Manufacturing and distribution sites (2)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| pharmaand GmbH Zweigniederlassung Scheibbs | Scheibbs, AT | EMA, FDA, Health Canada | |
| Pharmaand GmbH | Vienna, AT | EMA |
Organization relationships (1)
| Related organization | Relationship | Evidence |
|---|---|---|
| European Network of Gynaecological Oncological Trial Groups (ENGOT) | Co sponsors trial with | 1 |
Latest dated events (22)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2021-03-22 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2020-01-16 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2019-12-05 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2019-11-04 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2019-08-23 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 22 events.
Biomarker capability evidence (77)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| AR | Trial sponsor | Named in trial inclusion criteria |
| AR | Trial sponsor | Named in trial inclusion criteria |
| ATM | Trial sponsor | Named in trial inclusion criteria |
| ATM | Trial sponsor | Named in trial inclusion criteria |
| ATM | Trial sponsor | Primary endpoint in a Phase 3 trial |
Showing 5 of 77 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.